Login to Your Account


PARIS – The long-awaited reform that would untangle red tape and speed up market access in the U.K. for innovative medications and medical devices hit a roadblock called Brexit, a British exit from the European Union (EU).

LONDON – PTC Therapeutics Inc.'s muscular dystrophy therapy Translarna has survived intense scrutiny by NICE to emerge with a recommendation that it is funded under a managed access agreement.

HAMBURG – By late Wednesday afternoon, 18 drug developers filed applications for inclusion in the first batch of projects to benefit from a suite of regulatory supports under the EMA's priority medicines initiative, Prime, which aims to accelerate the development and approval of medicines with the potential to make significant clinical impact in areas of unmet medical need.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: